Basal Insulin Substitution with Glargine or Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Patients—A Randomized Controlled Trial

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Diabetes Technology & Therapeutics

• Publication date

  2010-08-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/dia.2010.0062PMID 20687863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine

  2008cited by this paper
• Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?

  2008cited by this paper
• Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus.

  2007cited by this paper
• The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes

  2007cited by this paper
• The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes

  2007cited by this paper
• Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

  2006cited by this paper
• Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.

  2005cited by this paper
• Should minimal blood glucose variability become the gold standard of glycemic control?

  2005cited by this paper
• Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

  2005cited by this paper
• Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years

  2002cited by this paper
• Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

  2000cited by this paper
• Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes

  1996cited by this paper
• The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality

  1995cited by this paper
• Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified insulin regimens.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus.

  1993cited by this paper
• Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system.

  1979cited by this paper
• Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

  1978cited by this paper
• Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability

  1970cited by this paper

• A randomized controlled trial of one bag vs. two bag system of fluid delivery in children with diabetic ketoacidosis: Experience from a developing country☆,☆☆

  2018cites this paper
• Continuous Subcutaneous Insulin Infusion and Its Characteristics in Young People with Type 1 Diabetes with Optimal Glucose Control (Preprint)

  2018cites this paper
• Insulin Analogs Applied with Continuous Subcutaneous Insulin Infusion (Pump) in the Treatment of Diabetes

  2015cites this paper
• Insulin Requirements in Relation to Insulin Pump Indications in Type 1 Diabetes

  2015cites this paper
• Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes

  2014cites this paper
• Changes in Insulin Requirements From the Onset of Continuous Subcutaneous Insulin Infusion (CSII) Until Optimization of Glycemic Control

  2014cites this paper
• Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients

  2013cites this paper
• Comparison of Insulin Pump Therapy (Continuous Subcutaneous Insulin Infusion) to Alternative Methods for Perioperative Glycemic Management in Patients with Planned Postoperative Admissions

  2012cites this paper
• HTA report: new devices for the management of glycaemia in young diabetics

  2012cites this paper
• GLUCOSE VARIABILITY AND HYPOGLYCEMIA IN ADULT PATIENTS WITH TYPE 1 DIABETES

  2011cites this paper
• Clinical studies of glucose variability and hypoglycemia in adult patients with type 1 diabetes

  2011cites this paper
• Clinical Experience with Insulin Glargine in Type 1 Diabetes

  2010cites this paper